Correlation of the ratio of tp and dpd mrna expression levels in colorectal cancer with disease-free survival in 5-fu treated patients
CA 2479446 C · Owner: Porstmann, Baerbel · Inventors: Walter, Thomas; Porstmann, Baerbel; Krause, Friedemann
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a method for determining whether a patient suffering from cancer is susceptable to a treatment with a 5-Fluoro-Uracil analogon comprising a) determination of Thymidine Phosphorylase mRNA expression in a clinical sample b) determination of Dihydropyrimindine Dehydrogenase mRNA expression in said clinical sample and c) determination of the ratio of the value obtained in step a) and the value obtained in step b). If the ratio exceeds a certain cut off susceptability to 5-FU and/or 5-FU analoga can be expected.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 25, 2004 and granted May 7, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 25, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 25, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.